U.S. Court in Pennsylvania Confirms AndroGel Patent Lawsuit Was “Objectively Baseless”
- January 27, 2023
A federal court in Pennsylvania found January 19 that AbbVie Inc.’s patent lawsuit over a generic version of its popular testosterone replacement drug AndroGel was “objectively baseless” and granted partial summary judgment on the issue to direct wholesale purchasers in their antitrust lawsuit.
ARTICLE TAGS
You must be logged in to access this content.